NCT01210482 - Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | Biotech Hunter

Enrollment

1,050

Participants

Timeline

Start Date

August 24, 2010

Primary Completion Date

March 30, 2018

Study Completion Date

May 31, 2018

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Temsirolimus

The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.

Trial Locations (1)

Unknown

Kyusyu University Hospital, Fukuoka